# Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

> **NCT02027428** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 427 (actual)

## Conditions studied

- Squamous Cell Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Abraxane (Induction)
- **DRUG:** Carboplatin (Induction)
- **DRUG:** Abraxane (Maintenance)
- **OTHER:** Best Supportive Care (Maintenance)
- **DRUG:** Abraxane (Induction)
- **DRUG:** Carboplatin (Induction)
- **OTHER:** Best Supportive Care (Maintenance)

## Key facts

- **NCT ID:** NCT02027428
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-11
- **Primary completion:** 2017-09-15
- **Final completion:** 2019-08-01
- **Target enrollment:** 427 (ACTUAL)
- **Last updated:** 2020-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02027428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02027428, "Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02027428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*